11-5226690-C-T
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM2PM5PP3_StrongPP5_Very_Strong
The NM_000518.5(HBB):c.202G>A(p.Val68Met) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another nucleotide change resulting in the same amino acid substitution has been previously reported as Likely benign in UniProt. Another variant affecting the same amino acid position, but resulting in a different missense (i.e. V68A) has been classified as Likely benign.
Frequency
Consequence
NM_000518.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 36
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hemoglobinopathy Pathogenic:1
Variant summary: HBB c.202G>A (p.Val68Met) results in a conservative amino acid change located in the Globin domain of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251432 control chromosomes. c.202G>A has been reported in the literature in heterozygous state in multiple individuals affected with severe Haemolytic anaemia and were transfusion dependent in the early years of life (examples: Molchanova_1993, Jiang_2016, Pedroso_2017, Hamid_2019, Su_2019, Corrons_2022, Zhang_2023). These data indicate that the variant is very likely to be associated with disease. At-least two of these cases were reported as de novo (Pedroso_ 2017, Hamid_ 2019) however, most published cases were without a family history for the disease (Table 1 in Zhang_2023). The following publications have been ascertained in the context of this evaluation (PMID: 8330974, 28361590, 28670945, 30316205, 31084366, 35091138, 37457725). ClinVar contains an entry for this variant (Variation ID: 15536). Based on the evidence outlined above, the variant was classified as pathogenic. -
not provided Pathogenic:1
The HBB c.202G>A (p.Val68Met) variant (also known as Hb Bristol, Hb Alesha, Hb Bristol-Alesha) has been characterized as a unstable hemoglobin variant, reported in the heterozygous state in multiple individuals with transfusion-dependent, severe hemolytic anemia (PMIDs: 37457725 (2023), 35091138 (2022), 17654076 (2007), 15646651 (2004), 8704193 (1996), 8330974 (1993)), and occurred as a de novo variant in two families (PMIDs: 28670945 (2017), 30316205 (2019)). This variant has not been reported in large, multi-ethnic general populations (Genome Aggregation Database, http://gnomad.broadinstitute.org). Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is damaging. Based on the available information, this variant is classified as pathogenic. -
HEMOGLOBIN ALESHA Other:1
- -
HEMOGLOBIN BRISTOL Other:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at